Prudential Financial’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-92,510
| Closed | -$3.72M | – | 2493 |
|
|
2026
Q1 | $3.72M | Buy |
+92,510
| New | +$1.99M | ﹤0.01% | 1053 |
|
|
2025
Q3 | – | Sell |
-154,010
| Closed | -$2.67M | – | 2425 |
|
|
2025
Q2 | $2.67M | Sell |
154,010
-63,870
| -29% | -$1.18M | ﹤0.01% | 1243 |
|
|
2025
Q1 | $4.77M | Buy |
217,880
+19,820
| +10% | +$548K | 0.01% | 859 |
|
|
2024
Q4 | $6.32M | Sell |
198,060
-89,700
| -31% | -$2.7M | 0.01% | 786 |
|
|
2024
Q3 | $8.3M | Buy |
287,760
+42,500
| +17% | +$1.57M | 0.01% | 758 |
|
|
2024
Q2 | $9.41M | Sell |
245,260
-300
| -0.1% | -$13.6K | 0.01% | 666 |
|
|
2024
Q1 | $14.4M | Sell |
245,560
-81,000
| -25% | -$5.16M | 0.02% | 556 |
|
|
2023
Q4 | $19.5M | Buy |
326,560
+23,000
| +8% | +$1.17M | 0.03% | 453 |
|
|
2023
Q3 | $12M | Buy |
303,560
+126,480
| +71% | +$5.56M | 0.02% | 585 |
|
|
2023
Q2 | $16.1M | Sell |
177,080
-259
| -0.1% | -$22.3K | 0.02% | 502 |
|
|
2023
Q1 | $11.7M | Sell |
177,339
-42
| -0% | -$2.42K | 0.02% | 594 |
|
|
2022
Q4 | $9.17M | Sell |
177,381
-3,993
| -2% | -$212K | 0.02% | 662 |
|
|
2022
Q3 | $12.4M | Buy |
181,374
+13,744
| +8% | +$813K | 0.02% | 571 |
|
|
2022
Q2 | $7.58M | Sell |
167,630
-164,572
| -50% | -$7.5M | 0.01% | 754 |
|
|
2022
Q1 | $16.9M | Buy |
332,202
+151,932
| +84% | +$6.71M | 0.02% | 552 |
|
|
2021
Q4 | $8.74M | Buy |
180,270
+8,875
| +5% | +$349K | 0.01% | 764 |
|
|
2021
Q3 | $5.65M | Sell |
171,395
-12,745
| -7% | -$716K | 0.01% | 935 |
|
|
2021
Q2 | $11.6M | Buy |
184,140
+19,180
| +12% | +$990K | 0.02% | 711 |
|
|
2021
Q1 | $7.08M | Buy |
164,960
+200
| +0.1% | +$9.46K | 0.01% | 896 |
|
|
2020
Q4 | $9.43M | Buy |
164,760
+40,490
| +33% | +$1.71M | 0.02% | 763 |
|
|
2020
Q3 | $3.75M | Buy |
124,270
+35,016
| +39% | +$1.05M | 0.01% | 1030 |
|
|
2020
Q2 | $2.92M | Buy |
89,254
+792
| +0.9% | +$25.4K | 0.01% | 1176 |
|
|
2020
Q1 | $2.37M | Buy |
88,462
+15,966
| +22% | +$567K | 0.01% | 1284 |
|
|
2019
Q4 | $2.22M | Sell |
72,496
-35,364
| -33% | -$979K | ﹤0.01% | 1551 |
|
|
2019
Q3 | $2.63M | Sell |
107,860
-27,220
| -20% | -$749K | ﹤0.01% | 1445 |
|
|
2019
Q2 | $3.42M | Sell |
135,080
-23,860
| -15% | -$485K | 0.01% | 1327 |
|
|
2019
Q1 | $3.1M | Sell |
158,940
-64,320
| -29% | -$1.01M | 0.01% | 1364 |
|
|
2018
Q4 | $2.96M | Buy |
223,260
+39,130
| +21% | +$600K | 0.01% | 1325 |
|
|
2018
Q3 | $3.27M | Buy |
184,130
+49,230
| +36% | +$910K | ﹤0.01% | 1387 |
|
|
2018
Q2 | $2.97M | Buy |
+134,900
| New | +$3.1M | ﹤0.01% | 1454 |
|
Other funds holding APLS
Prudential Financial's APLS Position: Q2 2026 in Review
Prudential Financial sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 92,510 shares — an estimated $3.72M sold.
Prudential Financial first reported a position in APLS in Q2 2018 and held it in 30 quarters. The position peaked at $19.5M in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Prudential Financial reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Prudential Financial sold 92,510 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.72M.
- Prudential Financial first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 30 quarters.
- Prudential Financial's Apellis Pharmaceuticals position peaked at $19.5M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.